Araştırma Makalesi

Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations

Cilt: 4 Sayı: 2 29 Aralık 2022
PDF İndir
EN

Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations

Öz

Hypertension is a disease that can progress for many years without symptoms or complications. This disease can cause death and permanent damage to vital organs such as the kidney, heart, and brain. However, when hypertension is treated effectively, these risk factors may decrease significantly. Although many antihypertensive drugs are used in the treatment of hypertension, ACE inhibitors are a new class among these drugs, and their separation and quantitative determinations are important for the success of preclinical, biopharmaceutical, and clinical studies. For this reason, in this study, the simultaneous determination of cilazapril, benazepril, and quinapril from ACE inhibitors, the validation of the developed method, and the quantitative determination of commercial drug dosage forms are aimed. To obtain the optimum liquid chromatographic separation condition, a systematic approach based on the relationship between mobile phase pH and retention time was used. The mobile phase organic modified concentration and column temperature parameters, which are known to affect the retention times of the compounds, were kept constant. When deciding on these parameters, few experiments were carried out.

Anahtar Kelimeler

Destekleyen Kurum

Süleyman Demirel University Scientific Research Projects Coordination

Proje Numarası

4578-YL2-16

Teşekkür

Many thanks to Suleyman Demirel University for supporting to our study.

Kaynakça

  1. I. Maraj, J. N. Makaryus, A.Ashkar, S.I. McFarlane, A.N. Makaryus, Hypertension management in the high cardiovascular risk population, International Journal of Hypertension, 2013, 2013, 1-7.
  2. N.J. Brown, D.E. Vaughan, Angiotensin-converting enzyme inhibitors, Circulation, 97, 1998, 1411-1420.
  3. L. Brunton, B. Chabner, B. Knollman, Goodman and Gilman’s The Pharmacological Basis of Therapeutics (9. edition), 1996, New York, McGraw-Hill.
  4. R. Kumar, R. Sharma, K. Bairwa, R. Kumar Roy, A. Kumar, A. Baruwa, Modern development in ACE inhibitors, Der Pharmacia Lettre, 2(3), 2010, 388-419.
  5. B.G. Katzung, Basic & Clinical Pharmacology (12. edition), 2011, San Francisco, The McGraw-Hill Companies.
  6. S.D. Firke, K.R. Bhoi, K.R. Patil, S.D. Jayswal, A.R. Tekade, S.S. Chalikwar, A State-Of-The-Art Review on Applications of Different Analytical Techniques for Some ACE Inhibitors, Analytical Chemistry Letters, 10(1), 2020, 60-79.
  7. Y. Kazakevich, Y. Lobrutto, HPLC for Pharmaceutical Scientists (1. edition), 2007, Canada, Wiley-Interscience.
  8. V.R. Meyer, Practical High-Performance Liquid Chromatography (16. edition), 2010, United Kingdom, John Wiley and Sons, Ltd.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Analitik Kimya

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

29 Aralık 2022

Gönderilme Tarihi

17 Eylül 2022

Kabul Tarihi

23 Kasım 2022

Yayımlandığı Sayı

Yıl 2022 Cilt: 4 Sayı: 2

Kaynak Göster

APA
Kuzucanlı, E., Çubuk Demiralay, E., Daldal, Y. D., Üstün, Z., Konçe, İ., & Alsancak, A. G. (2022). Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations. Turkish Journal of Analytical Chemistry, 4(2), 103-110. https://doi.org/10.51435/turkjac.1176649
AMA
1.Kuzucanlı E, Çubuk Demiralay E, Daldal YD, Üstün Z, Konçe İ, Alsancak AG. Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations. TurkJAC. 2022;4(2):103-110. doi:10.51435/turkjac.1176649
Chicago
Kuzucanlı, Erdem, Ebru Çubuk Demiralay, Yaşar Doğan Daldal, Zehra Üstün, İlkay Konçe, ve Abbase Güleren Alsancak. 2022. “Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations”. Turkish Journal of Analytical Chemistry 4 (2): 103-10. https://doi.org/10.51435/turkjac.1176649.
EndNote
Kuzucanlı E, Çubuk Demiralay E, Daldal YD, Üstün Z, Konçe İ, Alsancak AG (01 Aralık 2022) Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations. Turkish Journal of Analytical Chemistry 4 2 103–110.
IEEE
[1]E. Kuzucanlı, E. Çubuk Demiralay, Y. D. Daldal, Z. Üstün, İ. Konçe, ve A. G. Alsancak, “Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations”, TurkJAC, c. 4, sy 2, ss. 103–110, Ara. 2022, doi: 10.51435/turkjac.1176649.
ISNAD
Kuzucanlı, Erdem - Çubuk Demiralay, Ebru - Daldal, Yaşar Doğan - Üstün, Zehra - Konçe, İlkay - Alsancak, Abbase Güleren. “Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations”. Turkish Journal of Analytical Chemistry 4/2 (01 Aralık 2022): 103-110. https://doi.org/10.51435/turkjac.1176649.
JAMA
1.Kuzucanlı E, Çubuk Demiralay E, Daldal YD, Üstün Z, Konçe İ, Alsancak AG. Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations. TurkJAC. 2022;4:103–110.
MLA
Kuzucanlı, Erdem, vd. “Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations”. Turkish Journal of Analytical Chemistry, c. 4, sy 2, Aralık 2022, ss. 103-10, doi:10.51435/turkjac.1176649.
Vancouver
1.Erdem Kuzucanlı, Ebru Çubuk Demiralay, Yaşar Doğan Daldal, Zehra Üstün, İlkay Konçe, Abbase Güleren Alsancak. Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations. TurkJAC. 01 Aralık 2022;4(2):103-10. doi:10.51435/turkjac.1176649

Cited By

...